Invitrogen Closes Acquisition of Sentigen
 
Invitrogen this week said that it has closed its acquisition of Sentigen Holding.
 
The $25.9 million cash deal was announced in September (see BioCommerce Week 9/6/2006). Invitrogen paid $3.37 per share for the Phillipsburg, NJ-based company, which will become part of Invitrogen’s Discovery Sciences division, located in Madison, Wis.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.